Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1B | P01584 | 5/20 | 0.49 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.48 |
| ▸ | NLRP3 | Q96P20 | 4/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | PRKCZ | Q05513 | 8/20 | 0.44 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.43 |
| ▸ | LATS1 | O95835 | 1/20 | 0.42 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29275723 | 1.00 | IL1B (0.49) | IL1BCHEK2CHEK1NLRP3KCNH2 | |
| SCHEMBL29276000 | 0.97 | IL1B (0.51) | IL1BCHEK2CHEK1NLRP3KCNH2 | |
| SCHEMBL30214375 | 0.97 | IL1B (0.51) | IL1BCHEK2CHEK1NLRP3KCNH2 | |
| Hydrochloric Acid SCHEMBL30214836 | 0.96 | IL1B (0.50) | IL1BCHEK2CHEK1NLRP3KCNH2 | |
| Hydrochloric Acid SCHEMBL29276166 | 0.96 | IL1B (0.50) | IL1BCHEK2CHEK1NLRP3KCNH2 | |
| Formic Acid SCHEMBL30994511 | 0.96 | IL1B (0.46) | IL1BCHEK2CHEK1NLRP3KCNH2 | |
| Formic Acid SCHEMBL29275602 | 0.96 | IL1B (0.46) | IL1BCHEK2CHEK1NLRP3KCNH2 | |
| SCHEMBL30624999 | 0.94 | IL1B (0.51) | IL1BCHEK2CHEK1NLRP3KCNH2 | |
| Formic Acid SCHEMBL30214139 | 0.93 | IL1B (0.47) | IL1BCHEK2CHEK1NLRP3KCNH2 | |
| SCHEMBL31043271 | 0.91 | IL1B (0.56) | IL1BCHEK2CHEK1NLRP3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240262806-A1 | INHIBITORS OF NLRP3 | PCT THERAPEUTICS, INC. (US) | 2024-08-08 | — | — | US | claimed |
| CN-118302417-A | NLRP3 inhibitors | PTC医疗公司 | 2024-07-05 | — | — | CN | claimed |
| EP-4392414-A1 | INHIBITORS OF NLRP3 | PTC Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | claimed |
| WO-2023028534-A1 | INHIBITORS OF NLRP3 | PTC THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | claimed |
| US-20240262806-A1 | INHIBITORS OF NLRP3 | PCT THERAPEUTICS, INC. (US) | 2024-08-08 | — | — | US | disclosed |
| CN-118302417-A | NLRP3 inhibitors | PTC医疗公司 | 2024-07-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262806-A1 | INHIBITORS OF NLRP3 | NLRP3, NOD1, NLRP1 | IL1B 10/4885CHEK2 4518/4885CHEK1 4276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.